8th April 2021
- 0 comments
Scottish bio-tech company, BioCaptiva, has developed a novel next generation “liquid biopsy” technology device that could revolutionise the early diagnosis and monitoring of difficult to detect cancers. The University of Edinburgh spin-out has raised over £1m in seed funding from Edinburgh-based business angel investment syndicate, Archangels, and Scottish Enterprise, to help develop the technology. To prepare the company for this next stage in its development, BioCaptiva has appointed Dr Frank Armstrong FRCPE as non-executive chairman and Dr Stephen Little as a non-executive director.
...In order to read the full story we need you to be registered with us, please click the links below to login or register.